AZ1366: An inhibitor of tankyrase and the canonical Wnt pathway that limits the persistence of non-small cell lung cancer cells following EGFR inhibition

PURPOSE: The emergence of EGFR-inhibitors such as gefitinib, erlotinib and osimertinib has provided novel treatment opportunities in EGFR-driven non-small cell lung cancer (NSCLC). However, most patients with EGFR-driven cancers treated with these inhibitors eventually relapse. Recent efforts have i...

詳細記述

保存先:
書誌詳細
出版年:Clin Cancer Res
主要な著者: Scarborough, Hannah A, Helfrich, Barbara A, Casás-Selves, Matias, Schuller, Alwin G, Grosskurth, Shaun E, Kim, Jihye, Tan, Aik-Choon, Chan, Daniel C, Zhang, Zhiyong, Zaberezhnyy, Vadym, Bunn, Paul A, DeGregori, James
フォーマット: Artigo
言語:Inglês
出版事項: 2016
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5354947/
https://ncbi.nlm.nih.gov/pubmed/27663586
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-16-1179
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料